Safety and efficacy of COVID-19 hyperimmune globulin (HIG) solution in the treatment of active COVID-19 infection- Findings from a Prospective, Randomized, Controlled, Multi-Centric Trial

Devang Parikh, Alok Chaturvedi, Naman Shah, Piyush Patel, Ronak Patel, Suma Ray
doi: https://doi.org/10.1101/2021.07.26.21261119

Article usage

Article usage: July 2021 to January 2025

AbstractFullPdf
Jul 2021107611125
Aug 20212966377
Sep 20211236733
Oct 20211174519
Nov 20211535348
Dec 20211236630
Jan 20221019325
Feb 2022623225
Mar 202275817
Apr 202254912
May 2022641920
Jun 2022471014
Jul 202252711
Aug 202244711
Sep 20224538
Oct 202243512
Nov 2022452014
Dec 202237714
Jan 2023381115
Feb 202322119
Mar 202329124
Apr 202327710
May 202317515
Jun 20232377
Jul 202314315
Aug 2023251811
Sep 2023231013
Oct 20232288
Nov 202359620
Dec 20232905
Jan 20241939
Feb 20242867
Mar 202429912
Apr 202415111
May 20241235
Jun 20242368
Jul 202424915
Aug 20243079
Sep 20242669
Oct 20241479
Nov 202427411
Dec 202415418
Jan 20251429
Back to top
Posted July 27, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Safety and efficacy of COVID-19 hyperimmune globulin (HIG) solution in the treatment of active COVID-19 infection- Findings from a Prospective, Randomized, Controlled, Multi-Centric Trial
Devang Parikh, Alok Chaturvedi, Naman Shah, Piyush Patel, Ronak Patel, Suma Ray
medRxiv 2021.07.26.21261119; doi: https://doi.org/10.1101/2021.07.26.21261119
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area